Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Atorvastatin to Treat Pulmonary Sarcoidosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Joseph R. Fontana, M.D., National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00279708
First received: January 18, 2006
Last updated: June 30, 2016
Last verified: June 2016
Results First Received: June 30, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Sarcoidosis, Pulmonary
Intervention: Drug: Atorvastatin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited by national advertising (self-referrals), physician referrals, and through a medical clinic sponsored by the NIH, from March 2006 through March 2015.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects were screened by telephone and later during clinical testing a evaluation at the NIH Clinical Center. During this time subjects were evaluated to determine if they met the enrollment criteria, including that of treatment requiring disease, and relatively stable dosing prior to entry.

Reporting Groups
  Description
Intervention Group (Atorvastatin) Atorvastatin Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
Control Group (Placebo) Placebo In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study.

Participant Flow:   Overall Study
    Intervention Group (Atorvastatin)     Control Group (Placebo)  
STARTED     27 [1]   28 [2]
COMPLETED     24     23  
NOT COMPLETED     3     5  
Withdrawal by Subject                 2                 4  
Adverse Event                 1                 1  
[1] "Started" meaning randomized
[2] 28 were randomized, one additional subject was enrolled, but not randomized.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Intervention Group (Atorvastatin) Atorvastatin: Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
Control Group (Placebo) Placebo: In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study.
Total Total of all reporting groups

Baseline Measures
    Intervention Group (Atorvastatin)     Control Group (Placebo)     Total  
Number of Participants  
[units: participants]
  27     29     56  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     26     29     55  
>=65 years     1     0     1  
Age  
[units: years]
Mean (Standard Deviation)
  48.9  (7.95)     46.8  (9.12)     47.8  (8.57)  
Gender  
[units: participants]
     
Female     17     17     34  
Male     10     12     22  
Region of Enrollment  
[units: participants]
     
United States     27     29     56  



  Outcome Measures

1.  Primary:   The Steroid Sparing Period   [ Time Frame: 1 year ]

2.  Secondary:   Pulmonary Sarcoidosis Flares   [ Time Frame: 1 year ]
Results not yet reported.   Anticipated Reporting Date:   09/2016   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The recruitment goal of 96 subjects was not met due to slow accrual. The primary endpoint analysis was based on the available subject data.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Joseph Fontana, MD
Organization: The National Institutes of Health/ The National Heart, Lung, and Blood Institute
phone: 301-451-7740
e-mail: fontanaj@nhlbi.nih.gov


Publications:

Responsible Party: Joseph R. Fontana, M.D., National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00279708     History of Changes
Other Study ID Numbers: 060072
06-H-0072 ( Other Identifier: NIH NHLBI )
Study First Received: January 18, 2006
Results First Received: June 30, 2016
Last Updated: June 30, 2016
Health Authority: United States: Federal Government
United States: Food and Drug Administration